Galderma Group Aktie News

Aktie
WKN:  A407X6 ISIN:  CH1335392721 US-Symbol:  GDERF Branche:  Pharmazeutika Land:  Schweiz
177,00 €
+2,00 €
+1,14%
08:43:04 Uhr
Depot/Watchlist
Marktkapitalisierung *
38,76 Mrd. €
Streubesitz
22,61%
KGV
103,51
Dividende
0,15 CHF
Dividendenrendite
0,09%
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,98: MM6S7A
Werbung

Galderma Group News

06:00 Uhr - Businesswire
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its ...
04.12.25 - Businesswire
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer ...
17.11.25 - Businesswire
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American ...
14.11.25 - Businesswire
Galderma Completes Successful Placement of CHF 175 Million Bond
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR ...
05.11.25 - Businesswire
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft ...
23.10.25 - Businesswire
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along ...
24.09.25 - Businesswire
AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education
Galderma will present six posters with the latest updates from its science-​backed aesthetic portfolio at the Aesthetic & Anti-​Aging Medicine World Congress (AMWC) in Dubai, United ...
18.09.25 - Businesswire
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay
Galderma today announced Cetaphil, the dermatologist-​recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating ...
17.09.25 - Businesswire
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
Galderma today announced new data from a first-​of-its-kind real-​world clinical study conducted in China assessing the biological impact of different lifestyles and their associated ...
11.09.25 - Businesswire
EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch
Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates from its portfolio at the 34 th European Academy of Dermatology and Venereology ...
17.03.25 - PR Newswire
Galderma's Differin is helping destigmatize acne care with first in category Roblox experience
Galderma's Differin is helping destigmatize acne care with first in category Roblox experience PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »